S&P 500   3,120.54 (+0.00%)
DOW   28,012.23 (+0.03%)
QQQ   202.80 (-0.05%)
CGC   14.56 (-5.02%)
BABA   186.07 (+0.31%)
GE   11.38 (-1.22%)
T   39.45 (-0.13%)
F   8.97 (+0.22%)
PRI   130.64 (+0.01%)
BAC   32.91 (-0.06%)
DIS   148.01 (+2.31%)
S&P 500   3,120.54 (+0.00%)
DOW   28,012.23 (+0.03%)
QQQ   202.80 (-0.05%)
CGC   14.56 (-5.02%)
BABA   186.07 (+0.31%)
GE   11.38 (-1.22%)
T   39.45 (-0.13%)
F   8.97 (+0.22%)
PRI   130.64 (+0.01%)
BAC   32.91 (-0.06%)
DIS   148.01 (+2.31%)
S&P 500   3,120.54 (+0.00%)
DOW   28,012.23 (+0.03%)
QQQ   202.80 (-0.05%)
CGC   14.56 (-5.02%)
BABA   186.07 (+0.31%)
GE   11.38 (-1.22%)
T   39.45 (-0.13%)
F   8.97 (+0.22%)
PRI   130.64 (+0.01%)
BAC   32.91 (-0.06%)
DIS   148.01 (+2.31%)
S&P 500   3,120.54 (+0.00%)
DOW   28,012.23 (+0.03%)
QQQ   202.80 (-0.05%)
CGC   14.56 (-5.02%)
BABA   186.07 (+0.31%)
GE   11.38 (-1.22%)
T   39.45 (-0.13%)
F   8.97 (+0.22%)
PRI   130.64 (+0.01%)
BAC   32.91 (-0.06%)
DIS   148.01 (+2.31%)
Log in

Nektar Therapeutics Stock Price, Forecast & Analysis (NASDAQ:NKTR)

$17.63
-2.02 (-10.28 %)
(As of 11/18/2019 12:13 PM ET)
Today's Range
$17.56
Now: $17.63
$19.36
50-Day Range
$15.99
MA: $17.93
$20.48
52-Week Range
$15.64
Now: $17.63
$47.11
Volume118,478 shs
Average Volume2.75 million shs
Market Capitalization$3.10 billion
P/E Ratio4.66
Dividend YieldN/A
Beta2.62
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:NKTR
CUSIP64026810
Phone415-482-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.19 billion
Cash Flow$3.63 per share
Book Value$8.46 per share

Profitability

Net Income$681.31 million
Net Margins-352.83%

Miscellaneous

Employees618
Market Cap$3.10 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive NKTR News and Ratings via Email

Sign-up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.


Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating analysts' consensus estimates of ($0.73) by $0.17. The biopharmaceutical company had revenue of $29.22 million for the quarter, compared to analyst estimates of $26.42 million. Nektar Therapeutics had a negative return on equity of 26.60% and a negative net margin of 352.83%. The company's revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the company earned ($0.56) earnings per share. View Nektar Therapeutics' Earnings History.

When is Nektar Therapeutics' next earnings date?

Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Nektar Therapeutics.

What price target have analysts set for NKTR?

14 Wall Street analysts have issued twelve-month target prices for Nektar Therapeutics' stock. Their forecasts range from $16.00 to $43.00. On average, they expect Nektar Therapeutics' stock price to reach $30.08 in the next twelve months. This suggests a possible upside of 69.6% from the stock's current price. View Analyst Price Targets for Nektar Therapeutics.

What is the consensus analysts' recommendation for Nektar Therapeutics?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 1 sell rating, 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nektar Therapeutics.

What are Wall Street analysts saying about Nektar Therapeutics stock?

Here are some recent quotes from research analysts about Nektar Therapeutics stock:
  • 1. According to Zacks Investment Research, "Nektar reported encouraging third-quarter results wherein earnings and sales beat estimates. The company has a promising pipeline with several regulatory updates/data-readouts lined up for the next several quarters. Moreover, regular partnerships have enhanced the company’s financial position. The blockbuster collaboration deal with Bristol-Myers for NKTR-214 significantly boosted Nektar’s cash resources. It also has encouraging co-development deals with other pharma companies. The deals boost revenues and reduce expenses by sharing research costs. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company’s results in the future. Shares of the company have underperformed the industry so far this year." (11/11/2019)
  • 2. HC Wainwright analysts commented, "Our new 12-month, $24, vs. our prior $47 target on shares of Nektar is based on a 12-year DCF-driven, sum-of-the-parts analysis. Our DCF is driven by beta of 1.62, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2027." (8/13/2019)
  • 3. William Blair analysts commented, "We traveled with LeMaitre management last week as the company met with Barrington clients in Richmond, VA. This marked the second time in a month that we have spent time on the road with members of this management team and the messaging remains consistent and long-term bullish despite some short-term challenges." (6/14/2019)
  • 4. Mizuho analysts commented, "We expect these events to be important drivers for NKTR shares as we continue to believe that a majority of the company’s value lies in NKTR-214." (3/1/2019)

Has Nektar Therapeutics been receiving favorable news coverage?

Press coverage about NKTR stock has been trending very negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nektar Therapeutics earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Nektar Therapeutics.

Are investors shorting Nektar Therapeutics?

Nektar Therapeutics saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 33,260,000 shares, an increase of 7.6% from the September 15th total of 30,900,000 shares. Based on an average daily trading volume, of 3,910,000 shares, the days-to-cover ratio is presently 8.5 days. Currently, 19.2% of the company's stock are short sold. View Nektar Therapeutics' Current Options Chain.

Who are some of Nektar Therapeutics' key competitors?

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), Hawkins (HWKN), Netflix (NFLX), Gilead Sciences (GILD), Incyte (INCY), Puma Biotechnology (PBYI), Celgene (CELG) and Intel (INTC).

Who are Nektar Therapeutics' key executives?

Nektar Therapeutics' management team includes the folowing people:
  • Mr. Howard W. Robin, CEO, Pres & Director (Age 66)
  • Mr. Gil M. Labrucherie, Sr. VP & CFO (Age 47)
  • Mr. John Nicholson, Sr. VP & COO (Age 67)
  • Dr. Maninder Hora, Sr. VP of Pharmaceutical Devel. & Chief Technical Operations Officer (Age 65)
  • Dr. Stephen K. Doberstein, Chief R&D Officer (Age 60)

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (1.52%), Rhenman & Partners Asset Management AB (0.68%), Sumitomo Mitsui Trust Holdings Inc. (0.39%), Rice Hall James & Associates LLC (0.35%), Retirement Systems of Alabama (0.22%) and Rhumbline Advisers (0.22%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Dennis L Winger, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Katharina Otto-Bernstein, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.

Which major investors are selling Nektar Therapeutics stock?

NKTR stock was sold by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, First Trust Advisors LP, Nisa Investment Advisors LLC, Sumitomo Mitsui Trust Holdings Inc., Fjarde AP Fonden Fourth Swedish National Pension Fund, Rice Hall James & Associates LLC, State of Alaska Department of Revenue and Stoneridge Investment Partners LLC. Company insiders that have sold Nektar Therapeutics company stock in the last year include Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Katharina Otto-Bernstein, Lutz Lingnau, Maninder Hora, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.

Which major investors are buying Nektar Therapeutics stock?

NKTR stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Retirement Systems of Alabama, Railway Pension Investments Ltd, Brinker Capital Inc., California Public Employees Retirement System, Rhumbline Advisers, Commerzbank Aktiengesellschaft FI and Zeke Capital Advisors LLC. View Insider Buying and Selling for Nektar Therapeutics.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $17.73.

How big of a company is Nektar Therapeutics?

Nektar Therapeutics has a market capitalization of $3.12 billion and generates $1.19 billion in revenue each year. The biopharmaceutical company earns $681.31 million in net income (profit) each year or $3.78 on an earnings per share basis. Nektar Therapeutics employs 618 workers across the globe.View Additional Information About Nektar Therapeutics.

What is Nektar Therapeutics' official website?

The official website for Nektar Therapeutics is http://www.nektar.com/.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]


MarketBeat Community Rating for Nektar Therapeutics (NASDAQ NKTR)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  562 (Vote Outperform)
Underperform Votes:  340 (Vote Underperform)
Total Votes:  902
MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe NKTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NKTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel